Beijing Tiantan Biological Products Past Earnings Performance
Past criteria checks 5/6
Beijing Tiantan Biological Products has been growing earnings at an average annual rate of 16.9%, while the Biotechs industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 11.4% per year. Beijing Tiantan Biological Products's return on equity is 12.8%, and it has net margins of 23.8%.
Key information
16.9%
Earnings growth rate
14.2%
EPS growth rate
Biotechs Industry Growth | 11.3% |
Revenue growth rate | 11.4% |
Return on equity | 12.8% |
Net Margin | 23.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beijing Tiantan Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 5,331 | 1,269 | 718 | 183 |
31 Mar 24 | 5,110 | 1,165 | 733 | 155 |
31 Dec 23 | 5,180 | 1,110 | 739 | 140 |
30 Sep 23 | 5,371 | 1,167 | 726 | 99 |
30 Jun 23 | 5,062 | 1,063 | 714 | 90 |
31 Mar 23 | 4,848 | 1,018 | 660 | 109 |
31 Dec 22 | 4,261 | 881 | 629 | 122 |
30 Sep 22 | 4,207 | 803 | 627 | 144 |
30 Jun 22 | 4,191 | 808 | 625 | 147 |
31 Mar 22 | 3,970 | 733 | 616 | 142 |
31 Dec 21 | 4,112 | 760 | 599 | 133 |
30 Sep 21 | 3,628 | 700 | 546 | 125 |
30 Jun 21 | 3,702 | 692 | 536 | 117 |
31 Mar 21 | 3,535 | 659 | 511 | 113 |
31 Dec 20 | 3,446 | 639 | 492 | 119 |
30 Sep 20 | 3,398 | 641 | 469 | 99 |
30 Jun 20 | 3,276 | 601 | 458 | 125 |
31 Mar 20 | 3,334 | 611 | 456 | 119 |
31 Dec 19 | 3,282 | 611 | 452 | 117 |
30 Sep 19 | 3,394 | 580 | 478 | 135 |
30 Jun 19 | 3,271 | 563 | 446 | 112 |
31 Mar 19 | 3,083 | 531 | 431 | 103 |
31 Dec 18 | 2,931 | 509 | 383 | 102 |
30 Sep 18 | 2,929 | 568 | 338 | 85 |
30 Jun 18 | 2,671 | 532 | 273 | 118 |
31 Mar 18 | 2,485 | 1,228 | 293 | 107 |
31 Dec 17 | 2,483 | 1,173 | 370 | 91 |
30 Sep 17 | 2,362 | 1,077 | 581 | 55 |
30 Jun 17 | 2,256 | 1,038 | 655 | 0 |
31 Mar 17 | 2,330 | 313 | 676 | 0 |
31 Dec 16 | 2,138 | 257 | 631 | 0 |
30 Sep 16 | 1,756 | 151 | 414 | 0 |
30 Jun 16 | 1,709 | 55 | 405 | 0 |
31 Mar 16 | 1,624 | -3 | 373 | 0 |
31 Dec 15 | 1,618 | 10 | 380 | 0 |
30 Sep 15 | 1,545 | -88 | 483 | 0 |
30 Jun 15 | 1,567 | -46 | 509 | 0 |
31 Mar 15 | 1,723 | 46 | 550 | 0 |
31 Dec 14 | 1,827 | 128 | 576 | 0 |
30 Sep 14 | 2,026 | 291 | 528 | 0 |
30 Jun 14 | 2,018 | 377 | 482 | 0 |
31 Mar 14 | 1,905 | 371 | 436 | 0 |
31 Dec 13 | 1,837 | 372 | 390 | 0 |
30 Sep 13 | 1,827 | 459 | 335 | 0 |
Quality Earnings: 600161 has high quality earnings.
Growing Profit Margin: 600161's current net profit margins (23.8%) are higher than last year (21%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600161's earnings have grown by 16.9% per year over the past 5 years.
Accelerating Growth: 600161's earnings growth over the past year (19.4%) exceeds its 5-year average (16.9% per year).
Earnings vs Industry: 600161 earnings growth over the past year (19.4%) exceeded the Biotechs industry 10.1%.
Return on Equity
High ROE: 600161's Return on Equity (12.8%) is considered low.